Carregant...
501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
BACKGROUND: Bezlotoxumab (BEZ) was approved in October 2016 for the prevention of recurrent C. difficile (rCDI) infection in patients receiving standard-of-care (SoC) antibiotic therapy for active CDI who are at high risk for CDI recurrence. Presently, there are little real-world data on recurrence...
Guardat en:
| Publicat a: | Open Forum Infect Dis |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6253562/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.510 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|